Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14567511 | 1.00 | CA1 (0.55) | CA1CA2HTTALDH1A1TBXAS1 | |
| SCHEMBL7066789 | 0.86 | CA1 (0.56) | CA1CA2HTTALDH1A1TBXAS1 | |
| SCHEMBL7066783 | 0.86 | CA1 (0.56) | CA1CA2HTTALDH1A1TBXAS1 | |
| SCHEMBL2405831 | 0.84 | TDP1 (0.44) | ALDH1A1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL2405829 | 0.84 | TDP1 (0.44) | ALDH1A1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL4906646 | 0.84 | KMT2A (0.49) | CA1CA2ALDH1A1MAPT | |
| SCHEMBL4909047 | 0.84 | KMT2A (0.49) | CA1CA2ALDH1A1MAPT | |
| SCHEMBL1195693 | 0.84 | KMT2A (0.49) | CA1CA2ALDH1A1MAPT | |
| SCHEMBL6820654 | 0.83 | CA1 (0.54) | CA1CA2HTTALDH1A1TBXAS1 | |
| SCHEMBL6820652 | 0.83 | CA1 (0.54) | CA1CA2HTTALDH1A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| EP-1521752-B1 | MACROCYCLES FOR THE TREATMENT OF CANCER | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | WOLFGANG RICHTER (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1567524-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | Richter, Wolfgang (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1521752-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | Gesellschaft fur Biotechnologische Forschung mbH (gbf) (DE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004048372-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | MORPHOCHEM AG KOMB CHEMIE (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004007492-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | GESELLSCHAFT FUER BIOTECHNOLGISCHE FORSCHUNG MBH (GBF) (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | TTPA, THPO, TERT | CA1 4725/4885CA2 4710/4885HTT 3693/4885 |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | CCNI, CCNB1, CCNC | CA1 3681/4885CA2 3910/4885HTT 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.